chinese retatrutide Buy (60 mg) | Order Research Peptides China Retatrutide Injection - GMP

02 Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Eli Lilly and Company Lilly Investor Relations press release 2025 TRIUMPH-4 topline announcement, December 11, 2025: 28.7% body weight loss in the highest studied arm at 68 weeks in 445 participants

Combined with Novo's existing peptide commitments (UBT-251, NNC-06620419), SP-2297 completes a four-program portfolio across modalities

The comprehensive safety profile supports its integration into existing pharmaceutical development pipelines with minimal regulatory complexities

Buyers remain responsible for lawful import, intended use, and batch-specific verification in their jurisdiction